Baylor Research Institute

Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Universitë De Bordeaux

Université D'angers

Centre Hospitalier Universitaire De Bordeaux

Centre Hospitalier Universitaire D'angers

Inserm (institut National De La Sante Et De La Recherche Medicale)

Patrick Blanco

Jacques F Banchereau

Sandra M Zurawski

SangKon Oh

Yong-Jun Liu

Anna Karolina Palucka

Hyemee Joo

Hideki Ueno

Shino Hanabuchi

Haruyuki Fujita

Pascale Jeannin

Eve-Marie Neidhart-Berard

Celine Beauvillain

Yves Delneste

Yahsou Delmas

Cecile Contin-bordes

Jean-francois Augusto

Mahyar Nouri-Shirazi

Frederic Berard

Cécile Contin-bordes

Jean-François Augusto

Céline Beauvillain

The present invention concerns clusterin for use in the treatment of thrombotic microangiopathies, and a pharmaceutical composition comprising clusterin for use in the treatment of thrombotic microangiopathies, said composition not comprising von Willebrand factor protease. The present invention also concerns an ex vivo method for stratifying a patient suffering, or likely to be suffering, from TMA, comprising the following steps: 1) measuring, in a biological sample from said patient, the amount Lof clusterin, and 2) comparing the amount Lmeasured in step 1) with an amount Lof clusterin by calculating the score S1=L/L, in which: •If S1≤1, the patient is considered to be likely to benefit from a treatment of the TMA with clusterin, •If S1>1, the patient is not considered to be likely to benefit from treatment of TMA with clusterin.

Clusterin for use in the treatment of thrombotic microangiopathies

Described herein are methods and compositions for treating autoimmunity and inflammatory conditions without non-specific suppression of the host immune system. In particular, the anti-OX40L antibodies described herein are unique in that they not only inhibit the differentiation of inflammatory T cells but also promote the generation and function of regulatory T cells by inducing IL-10 and inhibiting TNF-&#x3b1; and by reducing aberrant Th2 cell responses. Furthermore, the methods and compositions described herein eliminate or reduce aberrant T follicular helper cell&#x2014;(Tfh) responses that may contribute to the pathogenicity of autoimmune disease.

Antagonistic anti-OX40L antibodies and methods of their use

Novel antigen-presenting cells, including but not limited to dendritic cells, that are loaded with antigens from dead or dying cells including allogenic cell lines, and the methods for making such antigen-presenting cells are described. These loaded antigen-presenting cells induce therapeutic immune responses in humans. Such loaded antigen-presenting cells are useful in the management of cancer. Antigen-loaded dendritic cells prepared as described here can prime na&#xef;ve T cells to differentiate into effector cells able to recognize multiple and/or shared tumor antigens that are expressed either on the tumor cells that are used to load the dendritic cells and/or on other tumor cells. The cytotoxic T cells generated by exposure to antigen-loaded dendritic cells prepared as described here can be used in adoptive therapy. This induction of responses against multiple antigens shared between different cells, for instance tumor cells, as described here is important as it leads to broad immune responses.

Use of allogeneic cell lines to load antigen presenting cells to elicit or eliminate immune responses

The invention provides a method for treating an autoimmune disease in a subject by administering an interferon antagonist and a Flt3 ligand (Flt3L) antagonist. The invention also provides compositions containing one or more interferon antagonists, and one or more Flt3L antagonists, an in vitro assay for determining a subject's risk for developing an autoimmune disease, and kits for use, inter alia, with the assay.

Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays

Growing community of inventors

Verdelais, France

Patrick Blanco